Hikma Pharmaceuticals (LSE:HIK) Asset Impairment Charge : £0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Asset Impairment Charge?

Hikma Pharmaceuticals's Asset Impairment Charge for the six months ended in Dec. 2023 was £0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was £0 Mil.

Hikma Pharmaceuticals Asset Impairment Charge Historical Data

The historical data trend for Hikma Pharmaceuticals's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Asset Impairment Charge Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Hikma Pharmaceuticals Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0 Mil.

Hikma Pharmaceuticals Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals (LSE:HIK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines